Petrelintide: how it works and early weight-loss studies
Clinical review pending
Petrelintide mimics the satiety hormone amylin. What early studies show and which questions about its effects and safety remain open.
What is petrelintide?
Petrelintide is an experimental drug that mimics amylin, a satiety signal released by the pancreas. Zealand Pharma developed it under the code ZP8396, engineering it for greater stability and a long half-life so it can be given as a once-weekly injection. Development is a joint effort with Roche. A combination study with a separate incretin drug is also planned. Petrelintide is still in research and is not approved for any use.
How does petrelintide work?
Petrelintide activates amylin receptors 1, copying the satiety signal of the natural hormone. Three effects are linked to this, and together they are meant to reduce food intake:
-
Reduced appetite.
-
Slower emptying of the stomach.
-
Suppression of glucagon release. Source
The amylin system is distinct from the incretin systems GLP-1 and GIP. That is why petrelintide is also being studied in combination with incretin drugs. On its own, the mechanism described here says nothing yet about whether treatment outcomes are better. Source
Is petrelintide FDA-approved?
No. Petrelintide is not approved by the FDA or by any other drug regulator. According to the developers, pivotal Phase 3 trials are planned to begin. Phase 2 data in people with type 2 diabetes are also expected. Source
What does the research show?
The source article relies on a single Phase 2 trial. The ZUPREME-1 trial, listed on PubMed 1, studied people with obesity who did not have diabetes and reported the average weight loss at two time points shown in the table.
Mild nausea was the main side effect. Overall, according to the study, gastrointestinal tolerability was comparable to placebo. That gives us one positive placebo-controlled Phase 2 trial. Phase 3 trials have not been completed yet, and longer-term efficacy and safety are still to be established.
Studies at a glance
| Time point | Average weight loss |
|---|---|
| 28 weeks | About 9 to 10% |
| 42 weeks | Further loss to around 11% |
References provided in the source article
Sources: the ZUPREME-1 Phase 2 trial (Garvey et al., The Lancet Diabetes & Endocrinology, 2026, DOI: 10.1016/S2213-8587(26)00213-5 1 ), indexed on PubMed; and Zealand Pharma development updates.
Provenance and editorial review status
Adapted for Nutrient Desk from the source article. The claims and source attributions in the original text still require clinical review. This draft has not been cleared for indexing.